Hopital Prive Toulon Hyeres Sainte Marguerite
- Address
- lock Available on a paid plan
Hopital Prive Toulon Hyeres Sainte Marguerite - Oncology Research Center
Hopital Prive Toulon Hyeres Sainte Marguerite is a specialized oncology research center with a strong focus on urological cancers and advanced immunotherapy approaches. The center demonstrates particular expertise in conducting multi-phase clinical trials evaluating novel therapeutic combinations and adjuvant treatment strategies for high-risk cancer patients.
- Non-muscle invasive bladder cancer (NMIBC) research, including BCG therapy combinations and intravesical immunotherapy with TAR-200 and cetrelimab
- Advanced renal cell carcinoma trials utilizing checkpoint inhibitors such as nivolumab, ipilimumab, durvalumab, and tremelimumab
- High-risk prostate cancer studies evaluating adjuvant hormonal therapy, radiation therapy, and cabazitaxel chemotherapy
- Gastrointestinal and breast oncology trials including ctDNA-guided adjuvant treatment for colon cancer and genomic-based therapy for elderly breast cancer patients
The center's research portfolio emphasizes precision medicine approaches and immunotherapy combinations, particularly in the adjuvant setting for patients at high risk of recurrence. With active participation in Phase II and Phase III trials, the facility contributes to advancing treatment paradigms for genitourinary malignancies and developing biomarker-driven treatment strategies such as circulating tumor DNA testing. The center's involvement in international multi-arm randomized trials demonstrates its commitment to evidence-based oncology care and improving long-term outcomes for cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive Toulon Hyeres Sainte Marguerite
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of TAR-200 and Cetrelimab in High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin | Janssen Cilag International | Phase II | Not Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apalutamide | 1 | Unknown | 2016-01-27 | 2016-01-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.